URAEMIA IS NECESSARY FOR ERYTHROPOIETIN-INDUCED HYPERTENSION IN RATS
| Autor: | Martine Lartigue, Jean-Michel Poux, Claude Leroux-Robert, Rose-Anne Chaisemartin, Francois Xavier Galen |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Physiology medicine.medical_treatment Blood Pressure Hematocrit Nephrectomy Animal model Experimental proof hemic and lymphatic diseases Physiology (medical) Internal medicine Animals Medicine cardiovascular diseases Rats Wistar Cyclic GMP Erythropoietin Uremia Pharmacology medicine.diagnostic_test business.industry Remnant kidney Rats Disease Models Animal Endocrinology Blood pressure Creatinine Hypertension Kidney Failure Chronic Chronic renal failure business circulatory and respiratory physiology medicine.drug |
| Zdroj: | Clinical and Experimental Pharmacology and Physiology. 22:769-771 |
| ISSN: | 1440-1681 0305-1870 |
| DOI: | 10.1111/j.1440-1681.1995.tb01933.x |
| Popis: | 1. There is no experimental proof that renal insufficiency is a necessary condition for hypertension during erythropoietin treatment. 2. The present study compares the effect of 3 weeks treatment with r-hu EPO (50 i.u./kg) on systolic blood pressure (SBP), haematocrit and plasma cGMP in an animal model of chronic renal failure (remnant kidney model excision) and sham-operated rats. 3. Sub-total nephrectomy induced a significant fall in haematocrit and a significant increase in plasma creatinine levels. Treatment with r-hu EPO resulted in a significant haematocrit increase in uraemic as well as in non-uraemic rats. Despite this effect, r-hu EPO treatment had no effect on SBP in sham-operated rats. On the contrary, this treatment caused significant SBP elevation in uraemic rats; in these rats, SBP increase did not correlate with haematocrit increase. 4. Plasma cGMP concentrations were significantly higher in uraemic compared to sham-operated rats and were not modified by r-hu EPO treatment. 5. This study provides evidence that renal insufficiency in rats is a prerequisite for the development of hypertension during erythropoietin treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text